Clinical Trial Update: Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD [Phase 2]

View source ↗

Summary

This clinical trial entry describes a Phase 2 study evaluating the safety and efficacy of EG-301 for non-exudative (dry) age-related macular degeneration, which…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-exudative Age-related Macular Degeneration

Drugs mentioned

• EG-301

Snippet

Sponsor: Evergreen Therapeutics, Inc. | Conditions: Non-Exudative (Dry) Age-related Macular Degeneration (dAMD) | Phase 2 | Status: NOT_YET_RECRUITING